Myriad Reports 8 Percent Rise in Q4 Revenues; Stock Drops on Forecast | GenomeWeb

NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market Tuesday that its fourth quarter revenues rose 8 percent year over year.

The Salt Lake City-based molecular diagnostics firm brought in total revenues of $188.8 million for the three months ended June 30, compared to revenues of $174.1 million for the fourth quarter of 2013, beating the consensus Wall Street estimate of $187.7 million.

The firm's shares fell in Wednesday morning trade, however, after Myriad provided guidance for Fiscal Year 2015 below analysts' estimates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: founder mutation linked to some leukoencephalopathy cases, transcript and protein profiles of the kissing bug, and more.

BGI CEO Ye Yin says that mapping variation within the human genome will bring a "big data revolution" to healthcare, Wired UK writes.

All the images that investigators produce through their research present a challenge to share, Nature News reports.

The House of Representatives science committee has approved a measure that includes new rules for large National Science Foundation projects, ScienceInsider reports.